Introduction
BIO International Convention took place from 5-8 June 2023 in Boston, MA. It serves as a platform for biopharmaceutical companies, investors, and government leaders to exchange ideas, present research findings, and explore partnership opportunities in the field. And LiveSpo proudly presents LiveSpo NAVAX – the world’s first nasal probiotic spray.
This remarkable event brought together the brightest minds, trailblazers, and innovators in the biotechnology industry, and it is an honor for LiveSpo to be a part of it. Over the course of the convention, we had the opportunity to connect with industry leaders, engage in inspiring discussions, and showcase our groundbreaking probiotic solutions.
On June 5, 2023 – LiveSpo is the first representative from Vietnam to participate in the BIO International Convention in Boston, USA, an exhibition showcasing breakthrough biotechnology solutions. This demonstrates the remarkable development of the Vietnamese pharmaceutical field in the realm of biotechnology.
LiveSpo NAVAX – the World’s First Nasal Probiotic Spray
Spore Probiotics Technology
Dr. Nguyen Hoa Anh – R&D Director – Chairman of LiveSpo Pharma, presented LiveSpo’s breakthrough spore probiotics technology at the BIO International Convention 2023. These technologies feature liquid-form, multi-strain, high-concentration LiveSpo spore probiotics technology and Pre-activated SPL technology with the product LiveSpo NAVAX. The application of LiveSpo NAVAX has addressed 80% of the challenges faced by children under 2 years old infected with RSV without any available pharmaceutical treatments. How? Let’s find out more below.
Clinical Trials on LiveSpo NAVAX
Respiratory syncytial virus (RSV) and influenza virus are the leading cause of Upper Respiratory Tract Infections. With this in mind, the R&D team of LiveSpo and Vietnam National Children’s Hospital has conducted the initial assessment of supportive treatment effects of nasal probiotic spray liquid suspension Bacillus spores (Bacillus subtilis ANA4 and Bacillus clausii ANA39) – LiveSpo NAVAX in RSV and influenza virus-infected children in Vietnam National Children’s Hospital.
The results of the study
In detail, the group of patients using LiveSpo NAVAX (NAVAX group) had a 1-2 days faster recovery time in relieving typical symptoms in comparison with a control group, relying on each symptom (runny nose, difficulty breathing, dry rales, moist rales, chest depression, and fever).
After 48-h and 72-h of influenza and RSV treatment, respectively, the concentration of influenza virus, RSV, and two superinfected bacteria (Haemophilus influenza và Streptococcus pneumoniae) in nasopharyngeal samples of patients reduced by about 3 x 102 folds, 1 x 103 folds and more than 1x 104 folds respectively, while in the control group, there was found only 15-folds reduction in both RSV and influenza virus concentration but the concentration of H. Influenza was increased and decreased depending on the case.
The decrease of RSV, influenza virus, and superinfected bacteria concentration is relevant to the presence of spore probiotics B. subtilis and B. clausii in a nasopharyngeal sample of patients in the NAVAX group while these spores were not detected in the control group. Surprisingly, we did not record any case with abnormal changes in breathing, pulse, nasal irritation, or digestion.
This is the world’s first blind, randomized, and controlled clinical trial in children to demonstrate the safety and beneficial effects of the nasal probiotic spray product containing Bacillus spore probiotics. Given that, spraying LiveSpo Navax into the nasal cavity 3 times a day helps shorten the recovery time for typical symptoms of upper respiratory tract infection caused by RSV and influenza virus by 1-2 days, depending on each symptom. It also helps reduce the concentration of RSV, influenza virus, and super-infected bacteria in nasopharyngeal samples of patients at about 20-70 folds more effectiveness than physiological saline.
Why is nasal probiotic spray superior to the others?
Their superiority lies in their targeted and efficient approach to dispensing liquids or medications.
Unlike traditional packaging methods, such as bottles or droppers, nasal sprays provide a controlled and consistent dose with each spray which ensures accurate administration. This precision minimizes the risk of overuse or underuse, leading to better outcomes and enhanced safety. Nasal probiotic spray provides a convenient and user-friendly experience. The spray mechanism allows for easy application, even in hard-to-reach areas, making them suitable for various age groups.
In addition to that, the sealed and airtight design of nasal spray packaging helps maintain the integrity and potency of the contents, preventing contamination and degradation which ensures the consistency and effectiveness of each dose. Nasal sprays provide rapid absorption through the nasal mucosa, a region abundant in blood vessels, leading to a faster onset of action in comparison to other packaging approaches. This focused delivery proves especially beneficial for medications needing prompt relief, such as decongestants or allergy remedies.
LiveSpo NAVAX has emerged as the world’s first nasal probiotic spray.
After undergoing rigorous clinical trials aligned with US standards, LiveSpo NAVAX has emerged as the world’s first spore nasal probiotic spray. Its significant impact on reducing treatment duration for acute respiratory infections in children has been proven. LiveSpo NAVAX demonstrates an exceptional ability to reduce the load of Respiratory Syncytial Virus (RSV) by 600-fold and influenza virus by 900-fold. Nature – one of the International Scientific Reports, has published an article regarding LiveSpo NAVAX’s safety and remarkable efficacy with the title: Nasal-spraying Bacillus spores as an effective symptomatic treatment for children with acute respiratory syncytial virus infection.
During the BIO International Convention, LiveSpo will be engaging in B2B meetings with partners from various countries worldwide. Discussions will revolve around the potential and practical applications of breakthrough spore probiotics and opportunities for exclusive distribution of LiveSpo products in international markets. The Vietnamese representative will also host a booth and participate in thematic seminars to stay updated with scientific and technological advancements in developed countries.
Overall, this achievement represents a significant milestone in our journey to bring innovative and effective products to support digestive wellness worldwide. LiveSpo’s commitment is to continuous research and development, pushing boundaries, and delivering our customers the highest quality probiotic solutions.
Let’s take a look at how we STAND UP FOR SCIENCE with BIO 2023!
